Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation.
A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.
Steg
R E
RE
Department of Neurology, Creighton University School of Medicine, Omaha, NE 68131-2197, USA.
Kessinger
A
A
Wszolek
Z K
ZK
D019575:Blindness, Cortical / Q000139:chemically induced*; D016026:Bone Marrow Transplantation; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D012640:Seizures / Q000139:chemically induced*; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016559:Tacrolimus